GSK says no decision yet made on Horlicks business
Following reports that it was close to selling its Indian Horlicks business, GlaxoSmithKline on Thursday said only that it is considering a deal.
FTSE 100
8,139.83
17:09 26/04/24
FTSE 350
4,470.09
16:59 26/04/24
FTSE All-Share
4,423.59
17:14 26/04/24
GSK
1,653.00p
16:40 26/04/24
Pharmaceuticals & Biotechnology
22,773.26
16:59 26/04/24
This came a day after it had been suggested that Unilever was close to buying the Horlicks business and Glaxo's other India-listed consumer healthcare nutrition products for around $4bn, having entered exclusive talks with its fellow FTSE 100 company.
On Thursday, GSK, led by CEO Emma Walmsey, said that "consideration is being given to a potential transaction that includes a merger" of Bombay Stock Exchange-listed subsidiary GlaxoSmithKline Consumer Healthcare Limited.
"There can be no assurance that a transaction will result from the review process or the evaluation of this option nor has any decision on the matter been made by the company."
GSK owns a 72.5% stake in the BSE-listed business, which has a market cap of $4.2bn, plus a smaller Bangladesh-listed business.